Biocept, Inc. (NASDAQ:BIOC) has a beta value of 0.66 and has seen 20,692,364 shares traded in the recent trading session. The company, currently valued at $95.64 Million, closed the recent trade at $0.7295 per share which meant it gained $0.09 on the day or 14.74% during that session. The BIOC stock price is -57.64% off its 52-week high price of $1.15 and 71.21% above the 52-week low of $0.21. If we look at the company’s 10-day average daily trading volume, we find that it stood at 33.51 Million shares traded. The 3-month trading volume is 26.44 Million shares.

The consensus among analysts is that Biocept, Inc. (BIOC) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 2 have rated it as a Hold, with 2 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $0.

Biocept, Inc. (NASDAQ:BIOC) trade information

Sporting 12.93% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Jun 29 when the BIOC stock price touched $0.75 or saw a rise of 5.19%. Year-to-date, Biocept, Inc. shares have moved 148.64%, while the 5-day performance has seen it change -7.6%. Over the past 30 days, the shares of Biocept, Inc. (NASDAQ:BIOC) have changed 63.47%. Short interest in the company has seen 2.87 Million shares shorted with days to cover at 0.11.

Wall Street analysts have a consensus price target for the stock at $1.53, which means that the shares’ value could jump 109.73% from current levels. The projected low price target is $1 while the price target rests at a high of $2.06. In that case, then, we find that the current price level is +182.39% off the targeted high while a plunge would see the stock lose 37.08% from current levels.

Biocept, Inc. (BIOC) estimates and forecasts

1 analysts offering their estimates for the company have set an average revenue estimate of $1.45 Million for the current quarter. 2 have an estimated revenue figure of $1.3 Million for the next quarter concluding in June 01, 2020. Year-ago sales stood $1.02 Million and $1.19 Million respectively for this quarter and the next, and analysts expect sales will grow by 41.3% for the current quarter and 9.2% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +67.9% over the past 5 years. Earnings growth for 2020 is a modest +86.4% while over the next 5 years, the company’s earnings are expected to increase by 40%.